Serenex of Durham has initiated a phase 1 trial for SNX-5422, its novel heat shock protein 90 (Hsp90) inhibitor, which may be useful as a cancer treatment.(PRODUCTS)
Publication Date: 01-JUL-07
Publication Title: BT Catalyst
Format: Online

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

Serenex of Durham has initiated a phase 1 trial for...



More articles from BT Catalyst
Raleigh-based Ajinomoto AminoScience, a part of Ajinomoto USA,, a whol..., July 01, 2007
Pioneer Surgical Technology of Marquette, Mich., has purchased Encelle..., July 01, 2007
Netherlands-based Akzo Nobel, owner of Diosynth Biotechnology of Resea..., July 01, 2007
AAIPharma of Wilmington has acquired Instituto de Pesquisa Clinica de ..., July 01, 2007
Serenex, of Durham, has secured $31 million in financing, including a ..., July 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.